Article citationsMore>>

Stewart, W.C., Kolker, A.E., Stewart, J.A., et al. (2003) Conjunctival Hyperemia in Healthy Subjects after Short-Term Dosing with Latanoprost, Bimatoprost, and Travoprost. American Journal of Ophthalmology, 135, 314-320.
http://dx.doi.org/10.1016/S0002-9394(02)01980-3

has been cited by the following article:

• TITLE: Ocular Surface Disease Index in Glaucomatous Patients Treated with Bimatoprost

  AUTHORS: Italo Giuffrè

  KEYWORDS: Bimatoprost 0.01%, Bimatoprost 0.03%/Timolol 0.50% Fixed Combination, Glaucoma, OSDI, Timolol 0.50%

  JOURNAL NAME: Open Journal of Ophthalmology, Vol.4 No.2, May 14, 2014

  ABSTRACT: Objectives: To compare ocular surface changes induced via glaucoma treatment in patients using fixed combinations of bimatoprost 0.03%/timolol 0.50%, timolol 0.50% or bimatoprost 0.01% eye drops. Methods: This is a prospective, one center, open-label clinical trial. It was performed on 60 glaucoma patients between 01-01-2012 and 12-31-2012. These patients were randomly divided in three subgroups: bimatoprost 0.03%/timolol 0.50% fixed combination, timolol 0.50% and bimatoprost 0.01%. The Ocular Surface Disease Index (O.S.D.I.) was evaluated in all the glaucomatous patients of the three subgroups at basal time and after 6 and 12 months. All the results were statistically evaluated by Student t-test and one-way ANOVA. The results were considered statistically significant if p ost 0.01% and bimatoprost 0.03%/timolol 0.50% patients (p = 0.05) and between bimatoprost 0.01% and timolol 0.50% eye drops alone (p = 0.049). Conclusions: This is a clinical trial based not on the hypotonising effect of these drugs but on their tolerability. The drug which showed the best tolerability is bimatoprost 0.01%.